Cogent Biosciences (COGT) Cash from Financing Activities (2017 - 2021)
Historic Cash from Financing Activities for Cogent Biosciences (COGT) over the last 5 years, with Q4 2021 value amounting to $38.0 million.
- Cogent Biosciences' Cash from Financing Activities fell 6888.22% to $38.0 million in Q4 2021 from the same period last year, while for Dec 2021 it was $38.0 million, marking a year-over-year decrease of 8364.49%. This contributed to the annual value of $878.2 million for FY2025, which is 30952.62% up from last year.
- According to the latest figures from Q4 2021, Cogent Biosciences' Cash from Financing Activities is $38.0 million, which was down 6888.22% from $55000.0 recorded in Q3 2021.
- In the past 5 years, Cogent Biosciences' Cash from Financing Activities ranged from a high of $122.1 million in Q4 2020 and a low of -$734000.0 during Q4 2017
- In the last 5 years, Cogent Biosciences' Cash from Financing Activities had a median value of $85000.0 in 2019 and averaged $24.3 million.
- As far as peak fluctuations go, Cogent Biosciences' Cash from Financing Activities surged by 56363.64% in 2020, and later tumbled by 21643.84% in 2021.
- Over the past 5 years, Cogent Biosciences' Cash from Financing Activities (Quarter) stood at -$734000.0 in 2017, then skyrocketed by 153.81% to $395000.0 in 2018, then plummeted by 75.44% to $97000.0 in 2019, then soared by 125813.4% to $122.1 million in 2020, then crashed by 68.88% to $38.0 million in 2021.
- Its last three reported values are $38.0 million in Q4 2021, $55000.0 for Q3 2021, and -$85000.0 during Q1 2021.